T R Moukhtarian1, R E Cooper2, E Vassos3, P Moran4, P Asherson3. 1. King's College London, MRC social, genetic and developmental psychiatry centre, Institute of psychiatry, psychology and neuroscience, SE5 8AF London, UK. Electronic address: talar_rita.moukhtarian@kcl.ac.uk. 2. King's College London, MRC social, genetic and developmental psychiatry centre, Institute of psychiatry, psychology and neuroscience, SE5 8AF London, UK; Newham centre for mental health, unit for social and community psychiatry, Queen Mary University of London, UK. 3. King's College London, MRC social, genetic and developmental psychiatry centre, Institute of psychiatry, psychology and neuroscience, SE5 8AF London, UK. 4. Centre for academic mental health, School of social & community medicine, University of Bristol, UK.
Abstract
BACKGROUND: Emotional lability (EL) is an associated feature of attention-deficit/hyperactivity disorder (ADHD) in adults, contributing to functional impairment. Yet the effect of pharmacological treatments for ADHD on EL symptoms is unknown. We conducted a systematic review and meta-analysis to examine the effects of stimulants and atomoxetine on symptoms of EL and compare these with the effects on core ADHD symptoms. METHODS: A systematic search was conducted on the databases Embase, PsychInfo, and Ovid Medline® and the clinicaltrials.gov website. We included randomised, double-blind, placebo-controlled trials of stimulants and atomoxetine in adults aged 18-60 years, with any mental health diagnosis characterised by emotional or mood instability, with at least one outcome measure of EL. All identified trials were on adults with ADHD. A random-effects meta-analysis with standardised mean difference and 95% confidence intervals was used to investigate the effect size on EL and compare this to the effect on core ADHD symptoms. RESULTS: Of the 3,864 publications identified, nine trials met the inclusion criteria for the meta-analysis. Stimulants and atomoxetine led to large mean weighted effect-sizes for on ADHD symptoms (n=9, SMD=-0.8, 95% CI:-1.07 to -0.53). EL outcomes showed more moderate but definite effects (n=9, SMD=-0.41, 95% CI:-0.57 to -0.25). CONCLUSIONS: In this meta-analysis, stimulants and atomoxetine were moderately effective for EL symptoms, while effect size on core ADHD symptoms was twice as large. Methodological issues may partially explain the difference in effect size. Reduced average effect size could also reflect heterogeneity of EL with ADHD pharmacotherapy responsive and non-responsive sub-types. Our findings indicate that EL may be less responsive than ADHD symptoms overall, perhaps indicating the need for adjunctive psychotherapy in some cases. To clarify these questions, our findings need replication in studies selecting subjects for high EL and targeting EL as the primary outcome.
BACKGROUND: Emotional lability (EL) is an associated feature of attention-deficit/hyperactivity disorder (ADHD) in adults, contributing to functional impairment. Yet the effect of pharmacological treatments for ADHD on EL symptoms is unknown. We conducted a systematic review and meta-analysis to examine the effects of stimulants and atomoxetine on symptoms of EL and compare these with the effects on core ADHD symptoms. METHODS: A systematic search was conducted on the databases Embase, PsychInfo, and Ovid Medline® and the clinicaltrials.gov website. We included randomised, double-blind, placebo-controlled trials of stimulants and atomoxetine in adults aged 18-60 years, with any mental health diagnosis characterised by emotional or mood instability, with at least one outcome measure of EL. All identified trials were on adults with ADHD. A random-effects meta-analysis with standardised mean difference and 95% confidence intervals was used to investigate the effect size on EL and compare this to the effect on core ADHD symptoms. RESULTS: Of the 3,864 publications identified, nine trials met the inclusion criteria for the meta-analysis. Stimulants and atomoxetine led to large mean weighted effect-sizes for on ADHD symptoms (n=9, SMD=-0.8, 95% CI:-1.07 to -0.53). EL outcomes showed more moderate but definite effects (n=9, SMD=-0.41, 95% CI:-0.57 to -0.25). CONCLUSIONS: In this meta-analysis, stimulants and atomoxetine were moderately effective for EL symptoms, while effect size on core ADHD symptoms was twice as large. Methodological issues may partially explain the difference in effect size. Reduced average effect size could also reflect heterogeneity of EL with ADHD pharmacotherapy responsive and non-responsive sub-types. Our findings indicate that EL may be less responsive than ADHD symptoms overall, perhaps indicating the need for adjunctive psychotherapy in some cases. To clarify these questions, our findings need replication in studies selecting subjects for high EL and targeting EL as the primary outcome.
Authors: Tanya E Froehlich; William B Brinkman; James L Peugh; Alexandra N Piedra; Daniel J Vitucci; Jeffery N Epstein Journal: J Child Adolesc Psychopharmacol Date: 2019-12-16 Impact factor: 2.576
Authors: Ulrich Ebner-Priemer; Philip Asherson; Talar R Moukhtarian; Iris Reinhard; Paul Moran; Celine Ryckaert; Caroline Skirrow Journal: Borderline Personal Disord Emot Dysregul Date: 2021-02-12
Authors: Susan Young; Philip Asherson; Tony Lloyd; Michael Absoud; Muhammad Arif; William Andrew Colley; Samuele Cortese; Sally Cubbin; Nancy Doyle; Susan Dunn Morua; Philip Ferreira-Lay; Gisli Gudjonsson; Valerie Ivens; Christine Jarvis; Alexandra Lewis; Peter Mason; Tamsin Newlove-Delgado; Mark Pitts; Helen Read; Kobus van Rensburg; Bozhena Zoritch; Caroline Skirrow Journal: Front Psychiatry Date: 2021-03-19 Impact factor: 4.157
Authors: Joseph Biederman; Maura DiSalvo; K Yvonne Woodworth; Ronna Fried; Mai Uchida; Itai Biederman; Thomas J Spencer; Craig Surman; Stephen V Faraone Journal: Eur Psychiatry Date: 2020-02-24 Impact factor: 5.361
Authors: Philip Asherson; Lena Johansson; Rachel Holland; Tom Fahy; Andrew Forester; Sheila Howitt; Stephen Lawrie; John Strang; Susan Young; Sabine Landau; Lindsay Thomson Journal: Trials Date: 2019-12-02 Impact factor: 2.279